Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company will be managing orders and warehouse operations for Little's, Lacto-calamine, Tri-activ, I-feel, Ourdaily, and Sloan's through the Unicommerce platform
Subscribe To Our Newsletter & Stay Updated